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RESUMO
Estudo descritivo e transversal, desenvol-
vido com o objetivo de avaliar a Qualidade
de Vida (QV) de pacientes com câncer, sub-
metidos à quimioterapia. Para a coleta de
dados, utilizou-se o instrumento European
Organization for Research and Treatment
of Cancer – Quality of Life Questionnaire
Core-30 (EORTC QLQ-C30). A amostra cons-
titui-se de 30 pacientes que assinaram o
consentimento informado. Os dados foram
analisados pelo software SPSS. O QLQ-C30
mostrou que a pontuação média das fun-
ções física, cognitiva e social, e desempe-
nho de papel, variou de 71,26 a 75,12, de-
monstrando um nível satisfatório. Na fun-
ção emocional, a média foi baixa, de 55,46.
Nas escalas de sintomas, houve o predomí-
nio da insônia com uma média de 34,44,
seguida de dor (23,33) e fadiga (22,31). A
QV foi satisfatória em todos os domínios,
exceto a função emocional, que foi baixa,
demonstrando que os efeitos colaterais da
quimioterapia influenciam negativamente
a QV dos pacientes.
DESCRITORES
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ABSTRACT
This descriptive and cross-sectional study
aimed to assess the Quality of Life (QoL) of
cancer patients who were receiving chemo-
therapy. The instrument European Organi-
zation for Research and Treatment of Can-
cer – Quality of Life Questionnaire Core-30
(EORTC QLQ-C30) was used for data collec-
tion. The sample consisted of 30 patients
who signed the informed consent term.
Data were analyzed in SPSS software. The
QLQ-C30 showed that, for physical, cogni-
tive and social functions, and role perfor-
mance mean scores ranged from 71.26 to
75.12, demonstrating a satisfactory level.
In the emotional function, the mean score
was low (55.46). On the symptoms scales,
there were a predominance of insomnia,
with a mean score of 34.44, followed by
pain 23.33 and fatigue 22.31. The QoL was
satisfactory in all domains except for the
emotional function, which scored low dem-
onstrating that the collateral effects of che-
motherapy exert a negative influence on
patients’ quality of life.
KEY WORDS
Neoplasms.
Drug therapy.
Quality of life.
Nursing care.
Oncologic nursing.
RESUMEN
Estudio descriptivo y transversal desarrolla-
do con el objetivo de evaluar la Calidad de
Vida (CV) de pacientes con  cáncer someti-
dos a quimioterapia. Para la recolección de
datos, se utilizó el instrumento European
Organization for Research and Treatment of
Cancer – Quality of Life Questionnaire Core-
30 (EORTC QLQ-C30). La muestra se consti-
tuyó de 30 pacientes que firmaron el con-
sentimiento informado. Los datos fueron
analizados con el software SPS. El QLQ-C30
mostró que la puntuación promedio de las
funciones físicas, cognitiva y social y desem-
peño de papel varió de 71,26 a 75,12, de-
mostrando un nivel satisfactorio. En la fun-
ción emocional, el promedio fue bajo de
55,46. En las escalas de síntomas hubo el
predominio del insomnio con  un promedio
de 34,44, seguida de dolor 23,33 y fatiga
22,31. La CV fue satisfactoria en todos los
dominios excepto la función emocional que
fue baja demostrando que los efectos cola-
terales de la quimioterapia influyen negati-
vamente la CV de los pacientes.
DESCRIPTORES
Neoplasias.
Quimioterapia.
Calidad de vida.
Atención de enfermería.
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INTRODUCTION
Cancer has become a worldwide public health issue, as
its prevalence has increased among non-transmissible chronic
diseases. Therefore, there is a need for large financial invest-
ments, which causes both institutional and social burdens(1).
In Brazil, there were an estimated 466,730 new cancer
cases in 2008 and 2009. The most prevalent types of cancer,
apart from non-melanoma skin cancer, are prostate and lung
cancer among men, and breast and cervical cancer among
women. This profile is the same for the world in general(1).
The primary types of cancer treatment include surgery,
chemotherapy, radiotherapy, and biotherapy. Surgery is
usually the initial treatment of choice for several types of
cancer(2). Advancements in surgical techniques, and an im-
proved understanding of the evolution and intensive post-
operative care have made it possible to remove tumors from
almost any part of the body.
Chemotherapy is one of the most chosen modalities to
achieve cure, control and relief It involves the use of cyto-
toxic substances usually administered systemically (intra-
venous), and is classified according to its purpose, such as:
adjuvant chemotherapy, neoadjuvant chemo-
therapy, primary chemotherapy, palliative
chemotherapy, monochemotherapy, and
polychemotherapy(2).
The chemotherapy drug is usually well tol-
erated by the patients with moderate side ef-
fects that are managed by using appropriate
doses and taking care when using other drugs,
such as antiemetics. The main toxicities are
suppression of the bone marrow, immunosupression, nau-
sea and vomiting, alopecia, renal toxicity, heart toxicity, pul-
monary toxicity, neurotoxicity, gonadal lesions, and sterility(3).
The clinical consequences of chemotherapy include: the
induction of nausea and vomiting, esophagus lesions, frac-
tures, malnutrition, as well as water-electrolyte and acid-
base imbalance, which often lead to the patients refusing
to continue with the chemotherapy cycles, thus reducing
their health-related quality of life (HRQoL) and compromis-
ing treatment effectiveness(4).
Quality of Life (QOL) is often measured to evaluate clini-
cal trials with chemotherapy, to measure side effects. QOL
measurement is the best method to evaluate the patient’s
tolerance to treatment. Chemotherapy should be evaluated
considering two important aspects: the toxic effects on tu-
mor cells, as well as the positive and negative impacts on
patient quality of life.
QOL measurement in oncology started in the 1940s,
with a scale to evaluate the patient’s physical function and
condition of performance(5).
Now, QOL measurements are fundamental in evaluating
cancer treatment outcomes. The quality of life term is seen
as a multidimensional (physical, psychological, social, and
spiritual), subjective, dynamic, and bipolar concept(6).
OBJECTIVES
From this perspective, the present study aimed to mea-
sure the QOL of patients with cancer treated with antine-
oplastic chemotherapy.
Specific objectives included:
• Characterizing patients in chemotherapy via sociodemo-
graphic and clinical data (gender, age, marital status, educa-
tion level, religion, diagnosis, and performed treatment);
• Identifying QOL domains affected in cancer patients
on chemotherapy; and
• Associating sociodemographic and clinical data with
QOL of patients with cancer on chemotherapy treatment.
METHOD
This is a descriptive, cross-sectional study performed at
the Specialized Oncology Center (CEON) in the
city of Ribeirão Preto. It is a hospital that sees
patients in the Brazilian public health system
(the unified health system – SUS), as well as
those using health insurance or paying for pri-
vate services.
The sample consisted of 30 patients, who
met the following inclusion criteria: 18 years
or older, on chemotherapy, using the SUS pub-
lic service, and providing written consent.
Data collection was performed using a version of the Euro-
pean Organization for Research and Treatment of Cancer – Qual-
ity of Life Questionnaire Core-30 (EORTC QLQ-C30)(7), validated
for the Brazilian population. The QLQ-C30 is a QOL instrument
used in patients with cancer, and consists of 30 questions on
five functional scales: physical, cognitive, emotional, and social
functions, and role performance; three symptom scales: fatigue,
pain, and nausea and vomit; one general health condition / QOL
scale; and five other items that evaluate symptoms that cancer
patients often complain about: dyspnea, loss of appetite, in-
somnia, constipation and diarrhea, plus an item that evaluates
the financial burden caused by the disease and its treatment.
For the QLQ-C30 general health condition / QOL scales,
and on scales regarding physical, emotional, cognitive and
social functions, and role performance, scores closer to 100
meant the patient functioning was better or that these condi-
tions had improved. On the other hand, scores closer to 100
on the symptom and financial burden scales meant an in-
creased presence of the referred symptoms and difficulties.
The instrument was administered during the second-
ary adjuvant chemotherapy treatment, in the form of an
interview, from April to November 2006.
Quality of Life (QOL) is
often measured to
evaluate clinical trials
with chemotherapy, to
measure side effects.
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The data were analyzed using SPSS for Windows. The
reliability of the instrument was tested with Cronbach al-
pha (α) internal consistency test.
For the descriptive data analysis, the mean and standard
deviation values were calculated; an analysis of variance
(ANOVA) was used to test the differences between the so-
ciodemographic and clinical variables. In addition, the p-value
was used, with 0.05 considered statistically significant.
The research was approved by the research ethics com-
mittee at Hospital das Clínicas de Ribeirão Preto at Faculdade
de Medicina de Ribeirão Preto – University of São Paulo
(HCRP-FMRP-USP), under register number HCRP 12483/2004.
All information was kept confidential, and participants pro-
vided written consent, complying with the Brazilian Research
Ethics Commission (CONEP) Resolution 196/96(8).
RESULTS
A Brazilian study(9) used and validated the QLQ-C30 for
Brazilians, and the findings regarding the instrument’s in-
ternal consistency for the sample used in the study was
α=0.86, which was considered reliable.
The present study sample consisted of 30 patients, resi-
dents in the Ribeirão Preto region, 50% females and 50%
males. Most patients were more than 40 years, married,
retired, and Catholic (Table 1).
As for level of education, 27 (90%) of patients had com-
plete or incomplete elementary level education; only one
subject (3.3%) completed secondary-level education, and
two (6.6%) completed superior education.
Regarding clinical characteristics, 16 (53.3%) participants
had gastrointestinal cancer, 20% had breast cancer, one (3.3%)
had prostate cancer, and seven (23.3%) were in metastasis.
In terms of therapy, 24 (80%) had undergone surgery to
remove a tumor or for complete or partial removal of the
affected organ and/or surrounding nodes; 11 (36.7%) patients
underwent radiotherapy, eight underwent between one and
30 sessions, and three underwent more than 30 sessions.
The 30 patients were undergoing adjuvant chemo-
therapy treatment (i.e., after primary treatment – surgery
and/or radiotherapy). Most patients began chemotherapy
10 months after receiving the diagnosis, 11 (36.6%) of which
were undergoing the first chemotherapy cycle, and the
other 19 (63.3%) were between the second and sixth cycle.
Table 2 shows the chemotherapy protocols used, of
which 5-Fluorouracil (5-FU) was the most commonly used
chemotherapy in 13 (43.3%) patients.
Table 1 - Sociodemographic characteristics - Ribeirão Preto - 2006
Characteristics N %
Age group 40 60 years
60 80 years
15
15
50
50
Marital
status
Single
Married
Widowed
Others
3
16
7
4
10
53.3
23.3
13.3
Profession Health (university degree)
Merchant / Cattle breeder
Salesman / broker
Agriculturist
Driver
Seamstress / Hairdresser
Retired
2
4
1
1
3
3
16
6.7
13.3
3.3
3.3
10
10
53.3
Religion Catholic
Pentecostal
Spiritualist
Jehovah's Witness
Buddhist
18
6
4
1
1
60
20
13.3
3.3
3.3
Table 2 - Chemotherapy protocols used - Ribeirão Preto - 2006
Chemotherapy protocols used N %
5-Fluorouracil
5-Fluorouracil + Cyclophosphamide
5-Fluorouracil + Cisplatin
5-Fluorouracil+ Cyclophosphamide + Doxorubicin
5-Fluorouracil + Cyclophosphamide + Metrotexate
Epirubicin + Cyclophosphamide
Cisplatin + Araceptin
Cisplatin + Taxol
Taxol
Oral chemotherapy
13
1
3
3
2
3
1
1
2
1
43.3
3.3
10
10
6.7
10
3.3
3.3
6.7
3.3
As for the chemotherapy side effects, five (16.7%) pa-
tients reported gastrointestinal complaints, such as nau-
sea, vomiting, stomatitis, diarrhea, constipation, colic, and
abdominal bloating; three (10%) reported physical symp-
toms like: uncomfortable heat, thirst, general sickness,
weakness, sleepiness, insomnia, dizziness, pain, tremor, and
itching; one (3.3%) patients reported emotional problems
such as depression, anguish, and irritability; seven (23.3%)
patients reported gastrointestinal and physical effects; four
(13.3%) presented all three side effect types (gastrointesti-
nal, physical, and emotional); and 10 (33.3%) patients were
asymptomatic. These findings show that chemotherapy
caused side effects in 20 patients, and that gastrointestinal
side effects affected 16 patients.
On the QLQ-C30, the general health condition/QOL
reached a 69.71 (Table 3), demonstrating that these pa-
tients consider they have a reasonable quality of life. The
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and nausea and vomiting with 9.44. It can be inferred that
the presence of these symptoms affects the patients’ physi-
cal, emotional, and cognitive functions, consequently af-
fecting their mean global health measurement of 69.71.
As for the financial burden, the mean of 35.5 demon-
strated that although the treatment for the disease is com-
plex and costly, it had not posed major financial difficulties
on patients, and that the SUS service had provided cover-
age for the whole treatment.
ANOVA results with the sociodemographic and clinical
variables from the QLQ-C30 domains were significant with
p-value < 0.05 (Table 4).
Age was correlated with nausea and vomiting (NAV),
insomnia (INS), and loss of appetite (LOP). This shows there
is a significant difference between the age groups, with
symptoms being stronger in the younger group, ranging in
age from 40 to 60 years
The chemotherapy protocol was statistically significant
(p < 0.05) with the INS and cognitive function scales (CF),
and was highly significant (p < 0.001) with the pain, LOP,
and constipation (CON) scales. This shows a significant dif-
ference among the chemotherapy protocols. It is observed
that the greatest means occurred for the protocol of 5-Fluo-
rouracil (5-FU) + Cyclophosphamide + Doxorubicin, show-
ing that this protocol causes more side effects.
As for the diagnosis, the significant difference found
with the LOP scale shows that patients with metastasis
report a greater loss of appetite. The side effects reported
by the patients were statistically significant with the CF
scale, showing a greater mean for gastrointestinal side
effects.
physical, cognitive and social functions and role perfor-
mance mean values ranged between 71.26 and 75.12,
showing a satisfactory level. The mean emotional function
was low (55.46), showing that patients were nervous, de-
pressed, worried, and irritated.
Table 3 - QLQ-C30 scales - Ribeirão Preto - 2006 (mean and standard
deviation)
Scales Mean
Standard
Deviation
General health condition (GHC/ QOL) 69.71 3.80
Physical function (PF) 72.24 5.00
Role performance (RP) 72.93 6.09
Emotional function (EF) 55.46 5.93
Cognitive function (CF) 71.26 6.33
Social function (SF) 75.12 5.68
Fatigue (FAT) 22.31 5.26
Nausea and vomiting (NAV) 9.44 3.36
Dyspnea (DIS) 10.55 5.08
Pain 23.33 6.11
Insomnia (INS) 34.44 7.23
Loss of appetite (LAP) 14.44 5.46
Constipation (CON) 12.21 4.65
Diarrhea (DIA) 0.0 0.0
Financial difficulties (FDI) 35.5 7.48
In the symptom scale, insomnia prevailed with a 34.44
mean, followed by pain with 23.33, fatigue with 22.31, loss
of appetite with 14.44, constipation 12.21, dyspnea 10.55,
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Table 4 - QLQ-C30 with the sociodemographic and clinical data - Ribeirão Preto - 2006
Scale Socio-demographic
variable
Variable Mean SD P-value
NAV Age group 40 60 years
60 80 years
64.28
4.44
99.96
11.72
0.029*
INS Age group 40 60 years
60 80 years
384.33
104.41
446.25
262.11
0.045*
LAP Age group 40 60 years
60 80 years
199.93
8.88
373.67
19.77
0.050*
Pain CT Protocol 5FU + LV
5FU + Cycloph. + Doxo.
5FU + Cycloph. + Metrotexate
Epirubicin + Cycloph.
Taxol
56.35
500.00
266.65
9.58
208.15
140.81
500.00
330.01
5.53
176.56
0.001**
INS CT Protocol 5FU + LV
5FU + Cisplatin
5FU + Cycloph. + Doxo.
5FU + Cycloph. + Metrotexate
17.93
333.00
555.33
33.30
29.21
333.00
509.10
47.09
0.002*
LAP CT Protocol 5FU + LV
5FU + Cycloph. + Doxo.
5FU + Cycloph. + Metrotexate
Taxol
2.56
555.33
16.65
47.09
9.24
509.01
23.55
33.30
0.000**
CON CT Protocol 5FU + LV
5FU + Cycloph. + Metrotexate
Epirubicin + Cycloph.
12.81
33.30
11.10
21.66
47.09
19.23
0.000**
CF CT Protocol 5FU + LV
5FU + Cycloph. + Doxo.
5FU + Cycloph. + Metrotexate
Epirubicin + Cycloph.
Taxol
810.00
500.00
1000.00
560.00
166.50
222.52
500.00
00.00
484.97
235.47
0.051*
CF Side
effects
GI 1000.0 - 0.008*
Physical
Emotional
GI + Physical
GI + Physical + Emotional
890.00
670.00
478.57
335.00
190.53
-
355.17
410.97
SD = standard deviation; CT = chemotherapy; 5-FU = Fluorouracil; LV = Leucovorin; Cycloph = Cyclophosphamide; Doxo = Doxorubicin; GI= gastrointestinal.
*p < 0.05 is significant. **p < 0.001 is highly significant.
DISCUSSION
The sociodemographic characteristics of the sample in
this study portray the reality of patients attending the SUS:
people with a low educational level from the Ribeirão Preto
region. As for epidemiological aspects, this study is in a-
greement with the statistics that point out the cancer inci-
dence rate for people with more than 40 years of age(1).
Depending on the patient’s age, there were significant
differences in the NAV, INS, and LOP scales. It is likely that
this is due to the protocols used, with 5-FU being the most
commonly used drug in 13 (43.3%) patients, and toxol in two
(6.7%) patients. These two drugs are considered having a
moderate emetogenic effect. In order to classify the combi-
nation of the cytostatic drugs, the agent with the strongest
emetogenic effect should be considered. Of the protocols in
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this study, 5-FU was associated with drugs classified as hav-
ing a moderate emetogenic effect, but at low dosages(10).
Other factors besides the pharmacological characteris-
tics should be taken into consideration as causes of nausea
and vomiting, such as the patient’s age, as this study showed
that younger patients experienced more nausea and vom-
iting(3). In the present study, a difference was found in pa-
tients in the younger age range between 40 and 60 years
who reached greater means in the NAV, INS, and LOP scales.
As for the chemotherapy protocol, a significant differ-
ence was found in the pain, INS, LOP, CON, and CF scales.
The 5-FU + Cyclophosphamide + Doxorubicin protocol pre-
sented greater means, indicating more symptoms, whereas
smaller means were found in the CF scale with the Taxol
protocol. This suggests that the referred drugs affect cog-
nitive function. This result is likely associated to the strong
emetogenic effect of Cyclophosphamide and Doxorubicin;
therefore they cause more side effects, such as stomatitis,
nausea and vomiting, and anorexia.
A studyperformed with patients that received at least two
cycles of chemotherapy(11) showed that the patients pre-
sented changes in their taste and the most reported symp-
toms were: dry mouth, loss of appetite, nausea and vomit-
ing, all of which were associated with the Cisplatin and Doxo-
rubicin agents, which also caused a reduction in QOL.
In another study, 48% of the patients reported moder-
ate constipation and 17% reported serious constipation(12).
These symptoms were associated with the diagnosis of
metastasis in seven (23.3%) patients, and with the diagno-
sis of gastrointestinal cancer in 16 (60%) patients.
The chemotherapy protocol also affected the CF. The
protocols with the smallest means were Taxol and 5-FU +
Cyclophosphamide + Doxorubicin and Epirubicin + Cyclo-
phosphamide. This suggests that chemotherapy drugs have
mechanisms that harm cognitive function.
The evidence cognitive dysfunction by chemotherapy
drugs are shown in a study that reported that the mecha-
nisms causing such harms are leukoencephalopathy and the
inflammatory response in the brain, both induced by the
responses of cytokines, anemia, and early menopause(13).
Cognitive function is defined as a multidimensional con-
cept and refers to the domains that result in a healthy per-
formance of the brain, such as attention and concentra-
tion, executive and motor functions, processing fast infor-
mation, language, visual and spatial ability, and memory(14).
Chemotherapy is a systemic treatment with a strong im-
pact on tumor cell division. It causes toxicity because of the
deleterious effect it has on the body’s normal cell division,
such as the bone marrow or gastrointestinal tract. Neuro-
toxicity is a stronger side effect because the nervous system
consists of cells that divide slowly or do not divide at all.
The protocols involved in this study are described as
triggers of leukoencephalopathy (5-FU, Methotrexate,
Paclitaxel, and Cyclophosphamide) and inducers of the in-
flammatory process (Doxorubicin) that harm the cognitive
function, causing, for instance, lack of concentration, re-
duced visual and spatial ability, and reduced memory(13).
The side effects also affected the CF, with the smallest means
in patients with the strongest gastrointestinal, physical, and
emotional symptoms. A previous study found an associa-
tion between psychological factors, such as anxiety, stress,
and depression, with a worse CF(15). Another study found
that mental or physical fatigue have a negative influence
on CF(16). Results from the present study were consistent
with previous studies where the group with gastrointesti-
nal, physical, and emotional side effects had the smallest
CF means.
One study, which performed a two-year evaluation of
the QOL and cognitive function cancer patients undergo-
ing adjuvant CT, found that, in the beginning of the treat-
ment, 30% of the patients presented moderate to serious
cognitive impairment, which improved with time and
dropped to 5% in the second evaluation, performed two
years later(17). There was also an improved general QOL.
The diagnosis was statistically significant in the LOP
scale, as patients with metastasis had a greater mean in
this scale. Loss of appetite is the second most frequent
symptom in patients with advanced cancer, present in 65%
to 85% of cases(18).
It is crucial for nurses to evaluate the patient systemati-
cally, with close attention to the symptoms presented to
identify changes in cognitive function. (19) It is essential for
nurses to care for patients in the biological dimension and
considering their subjectivity, observing the signs they trans-
mit, and establishing empathy and emotional involvement
using communication skills.
CONCLUSIONS
This study evaluated the QoL in cancer patients with
chemotherapy. In the last few decades, there has been a
rise in the number of QoL studies in oncology, and, today,
these studies are indispensible. One cannot think about
increasing patient survival without increasing quality of life.
Measuring quality of life is a complex task because of
its subjective and multidimensional characteristics,. There-
fore, it is necessary to use validated and reliable instru-
ments. In this study, it was possible to test the reliability of
the EORTC QLQ-C30, which was a reliable and valid mea-
sure for QOL in cancer patients who were treated with an-
tineoplastic chemotherapy.
As for the sociodemographic aspects, the study sample
was homogeneous in terms of gender; most patients were
40 years or older, married, retired, Catholic, and with el-
ementary education. Regarding clinical aspects, most pa-
tients had gastrointestinal cancer and had undergone sur-
gery; all were in chemotherapy.
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The findings showed that the most affected QOL do-
mains were: insomnia, pain, and fatigue; as for the age
group variable, there was a statistically significant differ-
ence in nausea and vomiting, insomnia, and loss of appe-
tite in younger patients. Regarding the CT protocol, there
were statistically significant differences for the domains:
pain, insomnia, loss of appetite, constipation, and cogni-
tive function; and, depending on the chemotherapy proto-
col, the signs and symptoms (CT side effects, such as nau-
sea, vomiting, loss of appetite, and constipation were more
common and had a negative effect on cognitive function.
Nurses should be aware about these effects and evalu-
ate patients systematically using clinical instruments that
are validated and reliable to detect changes to the patients’
cognitive function. In addition, it is important for nurses to
identify the patients’ risks to plan health care actions that
include the prevention.
The results of the present study should be interpreted
with care. The sample size is small and the cross-sectional
design does not allow for evaluating the QOL changes through
time. Therefore, the study cannot be generalized to the whole
cancer population in chemotherapy. There is a need for lon-
gitudinal studies that measure the cancer patients’ QOL as
well as the impact of the treatment in daily life, because such
studies would identify the aspects that require greater at-
tention when planning the patients’ physical, mental, and
social rehabilitation. Hence, the present study can serve as
an aid for health professionals in their practice.
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